What is William Blair’s Estimate for Medtronic Q4 Earnings?

Medtronic plc (NYSE:MDT) – Equities researchers at William Blair decreased their Q4 2025 earnings per share estimates for shares of Medtronic in a report released on Tuesday, February 18th. William Blair analyst M. Andrew now forecasts that the medical technology company will post earnings of $1.59 per share for the quarter, down from their previous forecast of $1.62. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q2 2026 earnings at $1.39 EPS and Q4 2026 earnings at $1.64 EPS.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.03. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The business had revenue of $8.29 billion during the quarter, compared to the consensus estimate of $8.33 billion.

A number of other research firms have also recently commented on MDT. Wells Fargo & Company lowered their price target on Medtronic from $106.00 to $98.00 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a report on Wednesday. Truist Financial lowered their price target on Medtronic from $93.00 to $89.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. UBS Group boosted their price target on Medtronic from $85.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Robert W. Baird upped their price objective on Medtronic from $90.00 to $91.00 and gave the stock a “neutral” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $95.00.

Medtronic Stock Up 2.3 %

MDT stock opened at $89.95 on Friday. Medtronic has a twelve month low of $75.96 and a twelve month high of $93.08. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48. The stock has a market cap of $115.34 billion, a P/E ratio of 27.34, a PEG ratio of 2.46 and a beta of 0.84. The business’s 50-day moving average price is $86.08 and its 200-day moving average price is $87.10.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MDT. Signaturefd LLC increased its holdings in shares of Medtronic by 4.3% in the third quarter. Signaturefd LLC now owns 13,332 shares of the medical technology company’s stock valued at $1,200,000 after purchasing an additional 551 shares during the period. Commerzbank Aktiengesellschaft FI grew its holdings in Medtronic by 120.6% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 11,049 shares of the medical technology company’s stock valued at $995,000 after purchasing an additional 6,041 shares during the period. Wallington Asset Management LLC grew its holdings in Medtronic by 5.3% in the third quarter. Wallington Asset Management LLC now owns 193,129 shares of the medical technology company’s stock valued at $17,387,000 after purchasing an additional 9,694 shares during the period. Axecap Investments LLC acquired a new stake in Medtronic in the third quarter valued at approximately $470,000. Finally, International Assets Investment Management LLC grew its holdings in Medtronic by 8,908.6% in the third quarter. International Assets Investment Management LLC now owns 1,298,415 shares of the medical technology company’s stock valued at $116,896,000 after purchasing an additional 1,284,002 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In other news, EVP Brett A. Wall sold 12,437 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $90.00, for a total value of $1,119,330.00. Following the transaction, the executive vice president now directly owns 40,979 shares of the company’s stock, valued at approximately $3,688,110. This represents a 23.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Friday, December 27th were paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend was Friday, December 27th. Medtronic’s dividend payout ratio (DPR) is presently 85.11%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.